NEW YORK (TheStreet) -- JP Morgan initiated coverage on Jazz Pharmaceuticals  (JAZZ - Get Report) with an "overweight" rating and a $190 price target. The firm said the company is well positioned for organic growth or the possibility of an acquisition.

The stock was up 2.28% to $155.98 in pre-market trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

JAZZ Chart JAZZ data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.